Zefeng Xu
Overview
Explore the profile of Zefeng Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang Y, Liu L, Cui C, He J, Li C, Jia Y, et al.
Cancer Med
. 2025 Mar;
14(5):e70747.
PMID: 40047093
Background: Isolated 20q deletion [del(20q)] is a recurrent favorable abnormality in myelodysplastic syndrome (MDS) and may cause deletion of the ASXL1 gene. Meanwhile, ASXL1 mutations are also common in individuals...
2.
Qu S, Liu N, Sun Q, Wang H, Jia Y, Qin T, et al.
Am J Hematol
. 2025 Feb;
PMID: 39996459
No abstract available.
3.
Cai Y, Xu Z, Cui F, Pei S, Wei L, Weng Z, et al.
Opt Express
. 2024 Jun;
32(10):17837-17852.
PMID: 38858954
This study addresses the critical need for rapid and online measurement of liquid concentrations in industrial applications. Although the thermal lens effect (TLE) is extensively explored in laser systems for...
4.
Li F, Qin T, Li B, Qu S, Pan L, Zhang P, et al.
Leukemia
. 2024 May;
38(6):1334-1341.
PMID: 38714876
We investigated data from 180 consecutive patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) who were diagnosed according to the 2022 World Health Organization (WHO) classification of myeloid...
5.
Liu L, Li B, Xu Z, Qin T, Jia Y, Qu S, et al.
Br J Haematol
. 2024 Apr;
205(3):942-946.
PMID: 38654443
The criteria of myelodysplastic syndromes (MDS) with mutated SFB31 (MDS-SFB31) proposed by the 5th edition of the WHO classification (WHO 2022) and the International Consensus Classification (ICC) need validation. We...
6.
Wang X, Xiao Z, Qin T, Xu Z, Jia Y, Qu S, et al.
Hematology
. 2024 Apr;
29(1):2338509.
PMID: 38597818
Myelodysplastic syndromes (MDS) patients with DEAD-box helicase 41 () mutations have been reported to be treated effectively with lenalidomide; however, there are no randomized studies to prove it. Venetoclax and...
7.
Dai Y, Yuan H, Cao X, Liu Y, Xu Z, Jiang Z, et al.
ACS Nano
. 2024 Feb;
18(10):7379-7390.
PMID: 38411928
LaO nanoparticles (NPs) have shown great potential in agriculture, but cracking of plant sensitive tissue could occur during application, resulting in a poor appearance, facilitating entry for insects and fungi,...
8.
Huang H, Liu J, Yang L, Yan Y, Chen M, Li B, et al.
Blood Sci
. 2023 Nov;
5(4):258-268.
PMID: 37941916
Ruxolitinib is a cornerstone of management for some subsets of myeloproliferative neoplasms (MPNs); however, a considerable number of patients respond suboptimally. Here, we evaluated the efficacy of micheliolide (MCL), a...
9.
Pan N, Xue Y, Xu Z, Long Z, Li Z, Wang Y, et al.
Int J Biol Macromol
. 2023 Jun;
245:125577.
PMID: 37379944
In this study, graphene oxide/N-halamine nanocomposite was synthesized through Pickering miniemulsion polymerization, which was then coated on cotton surface. The modified cotton exhibited excellent superhydrophobicity, which could effectively prevent microbial...
10.
Yan Y, Qu S, Liu J, Li C, Yan X, Xu Z, et al.
Leuk Lymphoma
. 2023 Jun;
64(9):1605-1610.
PMID: 37354441
No abstract available.